Nuclear AGO2 promotes HFpEF by linking lipotoxicity to myocardial ketogenesis, suggesting a targetable pathway in metabolic disorder-related HFpEF.
The AGO2/HMGCS2 pathway mediates myocardial ketogenesis and exacerbates HFpEF in the setting of metabolic disorders, identifying a potential novel therapeutic target.
Absolute Event Rate: 0% vs 0%
These findings uncover that long-term Western-style HFD treatment captures some critical characteristics of HFpEF, characterized by diastolic dysfunction with left ventricular ejection fraction >50%. AGO2/HMGCS2 pathway links lipo-toxicity to ketone-toxicity in the heart, which provides new mechanistic insights and suggests a potential strategy to develop treatments against metabolism disorder-related HFpEF.
Jin et al. (Fri,) reported a other. Nuclear AGO2 promotes HFpEF by linking lipotoxicity to myocardial ketogenesis, suggesting a targetable pathway in metabolic disorder-related HFpEF.